PRIMA-1Met/APR-246/Eprenetapopt (hereafter defined as PRIMA-1Met) is the most clinically advanced agent targeting mutant p53, which has been shown to reactivate the pro-apoptotic functions of wt p53 in the mutated forms of p53, eventually exerting potent anti-tumor activity in preclinical models [18]. This evidence concerns the gene TP53 and neoplasm.